Suplementação de resveratrol por via sublingual: efeito sobre marcadores de estresse oxidativo e inflamatórios em pacientes renais crônicos hemodialisados

• Autor(a) principal: Hermes, Daniele da Silva
• Data de Publicação: 2018
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Universitário da Ânima (RUNA)
• Texto Completo: https://repositorio.animaeducacao.com.br/handle/ANIMA/3050
• topic: Resveratrol; Doença renal crônica; Estresse oxidativo; Inflamação

Introduction: Inflammation and oxidative stress are risk factors related to cardiovascular disease mortality in patients with chronic kidney disease (CKD). Resveratrol is a promising molecule in the treatment of CKD due to antioxidant and anti-inflammatory effects. Objective: To evaluate the effect of resveratrol on markers of oxidative stress and inflammation in renal hemodialysis patients. Methods: Clinical, randomized, double-blind, placebo-controlled trial of hemodialysis patients. Patients were randomized into two groups: resveratrol and placebo. One group (n = 21) received sublingual tablets containing 50 mg resveratrol two times a day for 30 days and another (n = 21), placebo tablets. Sociodemographic, clinical and anthropometric data were collected at the initial moment of the study. The KDQOL-SFTM quality of life evaluation questionnaire and the determination of oxidative stress markers (lipoperoxidation, GSH, carbonylated protein and myeloperoxidase) and inflammation (PCR, TNF-α, IL-1β, IL-10 and IL -6) before and after intervention. Results: 21 patients (placebo) and 19 (resveratrol) were included in the analyses. In the placebo group 62% were male and in resveratrol, 53%; mean age was 57.48 ± 10.72 and 59.74 ± 12.96 years in the placebo and resveratrol groups, respectively. The primary cause of CKD in the placebo group was polycystic kidney disease and in resveratrol, hypertension. The mean hemodialysis time was 51.24 ± 42.38 and 56.68 ± 44.61 months in the placebo and resveratrol groups, respectively. Baseline anthropometric data did not differ between groups. No statistical difference was observed in terms of quality of life, markers of oxidative and inflammatory stress, when the groups were compared. The approximate mean range of the markers was: 7-9 nmol/mg (TBARS); ~ 2 μmol/mg (GSH), 0.3-0.4 mmol/mg (carbonylated protein) and 5-7 U/mg (MPO). The proportion of patients with detectable levels was <31% (CRP), 5-9% (TNF-α), <5% (IL-1β), 5 -11% (IL-10) and <11% (IL-6). Conclusion: Sublingual resveratrol supplementation was not effective in the dosage tested. For future studies it is suggested to consider: initiating supplementation at earlier stages of CKD, evaluating increased supplementation time and exploring different routes of administration.